Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.69 |
| ▸ | ATG7 | O95352 | 1/20 | 0.69 |
| ▸ | UBA7 | P41226 | 1/20 | 0.69 |
| ▸ | NAE1 | Q13564 | 1/20 | 0.69 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.69 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.69 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1796354 | 1.00 | UBA6 (0.69) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL1796353 | 1.00 | UBA6 (0.69) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL20008036 | 0.84 | NAE1 (0.48) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL32662531 | 0.81 | NAE1 (1.00) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL1797979 | 0.81 | NAE1 (1.00) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL1797199 | 0.81 | NAE1 (1.00) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL11889885 | 0.81 | NAE1 (1.00) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL18631114 | 0.81 | NAE1 (0.46) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL32662695 | 0.80 | SLC29A1 (0.60) | UBA6ATG7UBA7NAE1UBA3 | |
| SCHEMBL32661821 | 0.79 | KDM4E (0.63) | UBA6ATG7UBA7NAE1UBA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARM INC (US) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | UBA6 2037/4885ATG7 2417/4885UBA7 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.